Innoviva Quick Ratio 2010-2024 | INVA
Historical quick ratio values for Innoviva (INVA) over the last 10 years.
Innoviva Quick Ratio Historical Data |
Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
2024-09-30 |
$0.37B |
$0.22B |
1.64 |
2024-06-30 |
$0.32B |
$0.03B |
11.40 |
2024-03-31 |
$0.27B |
$0.03B |
9.17 |
2023-12-31 |
$0.30B |
$0.04B |
7.96 |
2023-09-30 |
$0.26B |
$0.04B |
7.31 |
2023-06-30 |
$0.28B |
$0.04B |
7.02 |
2023-03-31 |
$0.25B |
$0.04B |
6.47 |
2022-12-31 |
$0.39B |
$0.14B |
2.87 |
2022-09-30 |
$0.38B |
$0.16B |
2.34 |
2022-06-30 |
$0.00B |
$0.13B |
0.00 |
2022-03-31 |
$0.00B |
$0.11B |
0.00 |
2021-12-31 |
$0.00B |
$0.01B |
0.00 |
2021-09-30 |
$0.00B |
$0.00B |
0.00 |
2021-06-30 |
$0.00B |
$0.01B |
0.00 |
2021-03-31 |
$0.00B |
$0.00B |
0.00 |
2020-12-31 |
$0.00B |
$0.01B |
0.00 |
2020-09-30 |
$0.00B |
$0.00B |
0.00 |
2020-06-30 |
$0.00B |
$0.01B |
0.00 |
2020-03-31 |
$0.00B |
$0.00B |
0.00 |
2019-12-31 |
$0.00B |
$0.01B |
0.00 |
2019-09-30 |
$0.00B |
$0.00B |
0.00 |
2019-06-30 |
$0.00B |
$0.01B |
0.00 |
2019-03-31 |
$0.00B |
$0.00B |
0.00 |
2018-12-31 |
$0.00B |
$0.01B |
0.00 |
2018-09-30 |
$0.00B |
$0.00B |
0.00 |
2018-06-30 |
$0.00B |
$0.01B |
0.00 |
2018-03-31 |
$0.00B |
$0.00B |
0.00 |
2017-12-31 |
$0.00B |
$0.04B |
0.00 |
2017-09-30 |
$0.00B |
$0.03B |
0.00 |
2017-06-30 |
$0.00B |
$0.03B |
0.00 |
2017-03-31 |
$0.00B |
$0.02B |
0.00 |
2016-12-31 |
$0.00B |
$0.02B |
0.00 |
2016-09-30 |
$0.00B |
$0.02B |
0.00 |
2016-06-30 |
$0.00B |
$0.02B |
0.00 |
2016-03-31 |
$0.00B |
$0.01B |
0.00 |
2015-12-31 |
$0.00B |
$0.01B |
0.00 |
2015-09-30 |
$0.00B |
$0.01B |
0.00 |
2015-06-30 |
$0.00B |
$0.01B |
0.00 |
2015-03-31 |
$0.00B |
$0.01B |
0.00 |
2014-12-31 |
$0.00B |
$0.01B |
0.00 |
2014-09-30 |
$0.00B |
$0.04B |
0.00 |
2014-06-30 |
$0.00B |
$0.05B |
0.00 |
2014-03-31 |
$0.38B |
$0.04B |
8.57 |
2013-12-31 |
$0.47B |
$0.08B |
5.60 |
2013-09-30 |
$0.51B |
$0.04B |
13.28 |
2013-06-30 |
$0.45B |
$0.04B |
11.62 |
2013-03-31 |
$0.47B |
$0.03B |
15.83 |
2012-12-31 |
$0.25B |
$0.03B |
8.46 |
2012-09-30 |
$0.28B |
$0.03B |
10.24 |
2012-06-30 |
$0.30B |
$0.03B |
11.60 |
2012-03-31 |
$0.00B |
$0.03B |
0.00 |
2011-12-31 |
$0.00B |
$0.05B |
0.00 |
2011-09-30 |
$0.00B |
$0.04B |
0.00 |
2011-06-30 |
$0.00B |
$0.04B |
0.00 |
2011-03-31 |
$0.00B |
$0.03B |
0.00 |
2010-12-31 |
$0.00B |
$0.04B |
0.00 |
2010-09-30 |
$0.00B |
$0.04B |
0.00 |
2010-06-30 |
$0.00B |
$0.04B |
0.00 |
2010-03-31 |
$0.00B |
$0.04B |
0.00 |
2009-12-31 |
$0.00B |
$0.04B |
0.00 |
2009-09-30 |
$0.00B |
$0.04B |
0.00 |
2009-06-30 |
$0.00B |
$0.04B |
0.00 |
2009-03-31 |
$0.00B |
$0.04B |
0.00 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$1.122B |
$0.310B |
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|